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Background:A discrepancy between characteristics of patients treated with carotid angioplasty and stent placement (CAS)
within and outside clinical trials, particularly characteristics with direct impact on clinical outcome, may limit general-
ization of clinical trial results. The objective of this study was to identify differences in demographic and clinical
characteristics and outcomes related to CAS in patients treated within clinical trials and those treated outside clinical trials
in a large national cohort.
Methods: We determined the frequency of CAS performed within and outside clinical trials and associated in-hospital
outcomes using data from the Nationwide Inpatient Survey data files from 2005 to 2009. All the in-hospital outcomes
were analyzed after adjusting for potential confounders using multivariate analysis.
Results:Of the 81,638 patients who underwent CAS, 16,078 (19.6%) underwent the procedure as part of a clinical trial.
The mean age of the patients was significantly lower in patients treated with CAS as part of a clinical trial than those
treated with CAS outside a clinical trial. The proportion of women and nonwhites was lower among patients treated with
CAS as part of a clinical trial. The in-hospital mortality was two-fold higher among patients treated with CAS outside
clinical trials (1.12% vs 0.53%; P  .0005). The rate of composite endpoint of stroke, cardiac events, and death was
significantly higher among patients treated with CAS outside clinical trials (P  .02). After adjusting for age, gender,
presence of renal failure, and hospital bed size, CAS performed as part of a clinical trial was associated with lower rates
of in-hospital mortality (odds ratio, 0.467; 95% confidence interval, 0.290-0.751; P  .0017) and composite endpoint
of stroke, cardiac events, and death (odds ratio, 0.752; 95% confidence interval, 0.594-0.952; P  .0180).
Conclusions: Our results suggest that CAS procedures performed as part of clinical trials was associated with lower rates
of in-hospital mortality and composite endpoint of stroke, cardiac events, and death in United States. These findings
highlight the need for strategies that ensure appropriate adoption of CAS to ensure that the benefits observed in clinical
trials can be replicated in general practice. ( J Vasc Surg 2012;56:317-23.)
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MOver the last few years, the U.S. Food and Drug
Administration (FDA) has approved several carotid artery
stents and distal protection devices. The approval of these
devices was based on prospective randomized or single-arm
studies conducted in United States.1-6 The recent results of
the Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST)7 demonstrated that the risk of the
composite primary outcome of stroke, myocardial infarc-
tion, or death did not differ significantly in the group
undergoing carotid artery stent (CAS) placement and the
group undergoing carotid endarterectomy (CEA) for pa-
tients with symptomatic or asymptomatic carotid artery
stenosis. Therefore, the question of interpretation of the
results and implementation of CAS into practice, particu-
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doi:10.1016/j.jvs.2012.01.030arly with the anticipated growth in carotid stent proce-
ures based on the results of CREST, is of paramount
mportance.8
A discrepancy between characteristics of patients
reated within and outside clinical trials, particularly char-
cteristics with direct impact on clinical outcome, may lead
o reduction in anticipated benefit in practice outside clin-
cal trials. Several professional organizations, including a
onsensus statement from the Brain Attack Coalition9 and
he American Heart Association/American Stroke Associ-
tion Council on Stroke10 have recommended outcomes
esearch programs to generate knowledge about treat-
ents, outcomes, and complications of CAS in practice to
onfirm that procedures and therapies are performed for
ppropriate indications, with rates of success and compli-
ations that are consistent with those observed in clinical
rials. We performed this analysis to test the hypothesis that
he rates of periprocedural events observed in patients
reated with CAS in clinical trials are lower than the rates
bserved in CAS performed outside clinical trials (real-
orld experience) in both patients with symptomatic or
symptomatic carotid artery stenosis.
ETHODS
The analysis was performed using the data from the
ationwide Inpatient Sample (NIS) from 2005 to 2009.
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August 2012318 Qureshi et alThe NIS is the largest all-payer inpatient care database in
the United States as part of the Healthcare Cost and
Utilization Project (HCUP) by the Agency for Healthcare
Research and Quality (AHRQ).11-13 Briefly, NIS focuses
on identification, tracking, and analyzing national trends in
health care utilization, access, charges, quality, and out-
comes based on data derived from approximately a 20%
stratified sample of U.S. community hospitals; approxi-
mately 5 to 8 million hospital stays and all discharge data
from approximately 1000 hospitals. The data comprises
more than 100 clinical and nonclinical variables associated
with hospital stays, including primary and secondary diag-
noses, primary and secondary procedures, patients’ admis-
sion and discharge status, and patient demographic infor-
mation (eg, gender, age, race/ethnicity, expected payment
source, total charges, and length of stay). To facilitate
production of national estimates, the NIS provides both
hospital and discharge weights. Detailed information on
the design of the NIS is available at http://www.hcup-
us.ahrq.gov.
We used the International Classification of Disease, 9th
Revision, Clinical Modification (ICD-9-CM) procedure
codes 00.63 or 00.64 to identify the patients admitted for
CAS with the corresponding diagnostic code for carotid
artery stenosis with (433.11) or without (433.10) stroke.
Patients who participated in the Investigational Device
Exemption (IDE) category B clinical trial were identified
by a secondary diagnosis of ICD-9-CM V 70.5 used in
claims for Medicare qualifying clinical trial services. This
national coverage policy is based on the article in
§1862(a)(1)(E) of the Social Security Act for all Medicare
carriers, intermediaries, Peer ReviewOrganizations, Health
Maintenance Organizations, and Competitive Medical
Plans. We used the criterion that has been used previously
to differentiate the symptomatic from asymptomatic pa-
tients with carotid artery stenosis.11 If a patient’s discharge
diagnosis (diagnostic fields 1-15) was “carotid artery steno-
sis without mention of stroke” with no accompanying
secondary diagnoses for transient ischemic attack (TIA;
ICD-9 code 435.9), they were classified as “asymptom-
atic.” If a patient’s discharge diagnosis was either “carotid
artery stenosis with stroke” or, if there was no mention of
stroke, but a secondary diagnosis code included that for
TIA, patients were classified as “symptomatic.” Cardiovas-
cular risk factor information was obtained from the AHRQ
comorbidity data collected for each patient.
The primary outcome measures for this analysis were
procedure-related complications, including postoperative
neurological complications, including cerebral infarction or
hemorrhage (ICD-9-CM codes 997.00–997.09) and post-
operative cardiac complications (ICD-9-CM code 997.1).
A patient undergoing CAS who had any of these codes
under one of their secondary ICD-9-CM diagnos-
tic codes (up to 15) was classified as having had peripro-
cedural stroke or cardiac complications. Secondary outcome
measures included discharge disposition. Discharge disposi-
tion is categorized into routine, home health care, short-term
hospital, and other facility, including intermediate care and tkilled nursing home, or death. We categorized routine dis-
harge as none or minimal disability and any other discharge
tatus as moderate-to-severe disability.
Statistical analysis. We compared patients’ age, gen-
er, race/ethnicity, clinical characteristics, and length of
tay, periprocedural stroke or cardiac complications, dis-
harge status, and hospitalization charges between patients
ho underwent CAS within clinical trials versus those who
nderwent CAS outside clinical trials. The statistical analy-
es were performed based on weighted numbers.14 We
sed SAS 9.1 software (SAS Institute Inc., Cary, NC) to
onvert raw counts generated from the NIS database into
eighted counts that we used to generate national esti-
ates. All analyses accounted for the complex sampling
esign and sample discharge weights of the NIS following
CUP-NIS recommendations.14 We used the 2 test for
ategorical data and analysis of variance for continuous data
o detect any significant differences in variables and end-
oints between patients who underwent CAS within versus
utside clinical trial settings. A logistic regression analysis
as used to identify the association between participation
n clinical trials and odds of (1) postprocedural stroke;
2) postprocedural cardiac complications; (3) in-hospital
eath; (4) composite of stroke, cardiac events, and death;
nd (5) none or minimal disability. We adjusted for age and
ender in the initial models and adjusted for all the variables
hat were significantly different in the univariate analysis
etween patients who underwent CAS within clinical trials
ersus those who underwent CAS outside clinical trials. We
erformed two additional logistic regression analyses for all
he endpoints in symptomatic and asymptomatic patients
sing the above-mentioned design.
ESULTS
Of the 81,638 patients who underwent CAS, 16,078
19.6%) underwent the procedure as part of a clinical trial.
he mean age of the patients was significantly higher, with
higher proportion of patients aged 80 years among
atients treated with CAS as part of a clinical trial than those
reated with CAS outside a clinical trial (Table I). The
roportion of women was lower among patients treated
ith CAS within clinical trials. There was also a trend in
ifference in race/ethnicity of patients in the two groups:
he proportion of whites was higher among patients treated
ith CAS as part of a clinical trial. The proportion of
atients with hypertension, diabetes mellitus, and conges-
ive heart failure was similar between the two groups, but
he proportion of patients with renal failure was lower
mong patients treated with CAS within clinical trials.
here was a higher rate of admission to large hospitals
based on number of beds) in the group of patients treated
ith CAS as part of a clinical trial.
The mean length of stay (days  standard deviation)
as 3.1  4.9 days in patients treated with CAS outside
linical trials versus 2.1  3.1 days in patients treated with
AS within clinical trials (P  .0001; see Table I). The
n-hospital mortality was two-fold higher among patients
reated with CAS outside clinical trials (1.12% vs 0.53%;
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Volume 56, Number 2 Qureshi et al 319P  .0005). The rate of composite endpoint of stroke,
cardiac events, and death was significantly higher among
patients treated with CAS outside clinical trials (P  .02).
The rate of moderate-to-severe disability at discharge was
significantly higher in patients treated with CAS outside
clinical trials compared with those treated within clinical
trials (8.65% vs 4.11%; P  .0001). The mean hospital
charges were $50,929 in patients treated with CAS outside
clinical trials compared with $40,722 in those treated
within clinical trials (P  .001).
After adjusting for age and gender, presence of renal
Table I. Characteristics and outcomes of patients with car
in groups defined by whether procedure is performed with
Pat
Overall number (%)
Gender
Women 26,4
Age (mean)  SD
Age strata (years)
65 17,8
65-79 34,2
80 13,4
Race/ethnicitya
White 43,4
Black 24
Hispanic 24
Other 27
Comorbid conditions
Hypertension 48,1
Diabetes mellitus 20,1
Congestive heart failure 70
Renal failure 60
US region
Northeast 12,6
Northcentral 15,2
South 25,8
West 11,8
Hospital bed size
Small 51
Medium 12,9
Large 47,0
Hospital location and teaching status
Rural 16
Urban nonteaching 24,0
Urban teaching 39,5
Length of stay
Total hospitalization charges $50,9
Discharge status
None or minimal disability 59,1
Moderate or severe disability 56
In-hospital complications
Postprocedural mortality 7
Postprocedural stroke 13
Postprocedural cardiac complications 14
Postprocedural stroke and or cardiac complications 26
Composite endpointb 32
NIS, Nationwide Inpatient Sample.
aRace/ethnicity is not uniformly reported in NIS database.
bComposite endpoint of postprocedural stroke, cardiac complications, and/failure, and hospital bed size, CAS performed within clini- 2al trials was associated with lower rates of none or minimal
isability (odds ratio [OR], 0.367; 95% confidence interval
CI], 0.230-0.588; P  .0001; Table II). After adjusting
or age, gender, renal failure, and hospital bed size, CAS
erformed within clinical trials was associated with lower
ates of in-hospital mortality (OR, 0.467; 95% CI, 0.290-
.751; P  .0017) and composite endpoint of stroke,
ardiac events, and death (OR, 0.752; 95% CI, 0.594-
.952; P  .0180). In the subgroup analysis, the rate of
one to minimal disability was higher among patients
reated within clinical trials for both asymptomatic (OR,
artery stenosis treated with carotid artery stent placement
outside clinical trials (NIS 2005-2009)
nts undergoing carotid artery stent placement
treated outside
ical trials
Patients treated within
clinical trials P value
5,560 16,078
40.28) 6086 (37.86) .0164
3  10.5 72.3  9.1 .0001
27.2) 2947 (18.2) .0001
52.3) 9519 (59.2)
20.5) 3611 (22.5)
85.06) 11,362 (89.22) .0927
4.71) 466 (3.65)
4.82) 451 (3.54)
5.39) 455 (3.57)
73.40) 12,074 (75.09) .2066
30.73) 4690 (29.16) .1054
10.69) 1568 (9.75) .2424
9.16) 1245 (7.74) .058
19.25) 3390 (21.08) .9838
23.21) 3784 (23.53)
39.47) 6088 (37.86)
18.05) 2816 (17.51)
7.96) 1830 (11.43) .0022
19.88) 1759 (10.99)
72.15) 12,410 (77.57)
2.48) 487 (3.04) .529
36.90) 6762 (42.26)
60.61) 8750 (54.69)
1  4.9 2.1  3.1 .0001
47,560-54,288) $40,722 (36,019-45,424) .0001
90.16) 15,330 (95.34) .0001
8.65) 662 (4.11) .0001
1.12) 85 (0.53) .0005
1.99) 283 (1.76) .3966
2.25) 295 (1.83) .2332
4.11) 564 (3.51) .1732
4.91) 619 (3.85) .0235
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August 2012320 Qureshi et al1.9; 95% CI, 1.3-2.9; P  .0028) patients. There was a
trend toward lower rates of composite endpoint among
asymptomatic patients (OR, 0.816; 95% CI, 0.6-1.0; P 
.109) but not in symptomatic patients (OR, 1.08; 95% CI,
0.6-1.9; P  .5) treated within clinical trials.
DISCUSSION
We found in our analysis that CAS performed within
clinical trials was associated with lower rates of in-hospital
mortality and composite endpoint of stroke, cardiac events,
and death in the United States. The mean hospital charges
were higher in patients treated with CAS outside clinical
trials compared with those treated within clinical trials.
These findings have important implications for generaliza-
tion of results derived from clinical trials evaluating CAS.
Another observational, retrospective cohort study15
identified similar challenges with adoption of CAS out-
side clinical trials by stratifying localities based on incre-
mental rates of CAS performed after Medicare coverage
was introduced. Localities with higher adoption of CAS
observed higher 90-day mortality, 270-day mortality,
and 270-day combined outcomes. Our study identifies
the differences between outcomes in CAS patients re-
cruited in clinical trials but does not explain the reasons.
There are several possibilities that may account for our
findings and implications that need to be considered. If
the patient population outside clinical trials has a higher
prevalence of adverse characteristics, then the benefit of
CAS observed in clinical trials is unlikely to be repro-
duced in general practice. If the differential results are
more likely to be related to operator-related factors, the
benefit of CAS observed in clinical trials is again unlikely
to be reproduced in general practice. Similarly, the cost-
effectiveness of the procedure that is currently derived
from data derived from clinical trials is less likely to be
acceptable.
It is very likely that patients treated with CAS within
clinical trials have more favorable characteristics than those
treated as part of routine practice (cherry-picking phenom-
enon).16 Therefore, the differences in outcomes observed
Table II. Multivariate analyses evaluating the effect of car
various discharge outcomes in patients treated with carotid
Outcomes
Unadjusted OR
OR (95% CI) P value
None to minimal disability 2.237 (1.809-2.767) .0001
Postprocedural stroke 0.877 (0.651-1.181) .3867
Postprocedural cardiac
complications 0.812 (0.560-1.177) .2708
Postprocedural mortality 0.469 (0.291-0.756) .0019
Composite endpointb 0.775 (0.614-0.978) .0316
CI, Confidence interval; NIS, Nationwide Inpatient Sample; OR, odds ratio
aModel adjusted for age, gender, renal failure, and hospital bed size.
bComposite endpoint of postprocedural stroke, cardiac complications, and/in our study could be predominantly due to differences in easeline clinical and angiographic characteristics. There is
dequate evidence from such comparisons between within
rial and outside trial patients for both CEA and aneurysm
mbolization. Such issues have been previously highlighted
n interpretation and application of the North American
ymptomatic Carotid Endarterectomy Trial (NASCET),
symptomatic Carotid Atherosclerosis Study (ACAS), and
he International Subarachnoid AneurysmTrial (ISAT). An
nalysis of 113,300 Medicare patients undergoing CEA
uring 1992 and 1993 in “trial hospitals” (those participat-
ng in NASCET and ACAS, n  86) and “nontrial hospi-
als” (all other nonfederal institutions performing CEAs,
 2613) reported17 that Medicare patients’ perioperative
ortality following CEA outside clinical trials was substan-
ially higher than that reported in the trials, even in those
nstitutions that participated in the randomized studies.
imilarly, the overall in-hospital mortality was 6% in ISAT18
randomized trial comparing endovascular and surgical an-
urysm treatment) compared with the 26% in-hospital
ortality observed for subarachnoid hemorrhage admis-
ions in the United States19,20 % in-hospital mortality in the
apanese Standard Stroke Registry Study.21 These observa-
ions suggest that patients treated in the NASCET, ACAS,
nd ISAT had more favorable baseline clinical and proce-
ural characteristics compared with those observed in the
eneral population questioning generalization of results.16
prominent difference between patients treated within
nd outside clinical trials was that those treated with CAS
utside clinical trials were younger and more likely to
e 65 years of age. In our previous analysis of patients
ndergoing CAS in the United States22 age 70 years was
n important predictor of postoperative stroke and cardiac
omplications post-procedure after adjustment for gender
nd other comorbid conditions. Therefore, the higher rate
f adverse events in patients treated with CAS outside
linical trials would have been augmented with comparable
roportion of older patients.
For trials involving the performance of CAS, the trial
teering and/or credentialing committee develops criteria
o ensure that practitioners have adequate experience and
artery stent placement performed within clinical trials on
ry stent placement (NIS 2005-2009)
adjusted for age and gender
OR adjusted for age, gender, and
potential confoundersa
R (95% CI) P value OR (95% CI) P value
7 (1.885-2.896) .0001 2.377 (1.914-2.951) .0001
0 (0.629-1.149) .2896 0.848 (0.627-1.146) .2822
1 (0.544-1.151) .2204 0.785 (0.540-1.142) .2056
3 (0.288-0.745) .0015 0.467 (0.290-0.751) .0017
6 (0.598-0.957) .0198 0.752 (0.594-0.952) .0180
ath.otid
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Volume 56, Number 2 Qureshi et al 321of the trial. The operators performing CAS outside clinical
trials are unlikely to be qualified to the same extent. The
variations in operator experience and impact on CAS out-
comes were highlighted by the difference in the results of
the Endarterectomy vs Angioplasty in Patients with Symp-
tomatic Severe Carotid Stenosis (EVA-3S) trial7,22 and
CREST trial. The 1-month stroke and death rate associated
with CAS was prominently higher in the EVA-3S trial
compared with CREST (9.6% and 5%, respectively). In
CREST, each interventionalist was required to submit data
on 10 to 30 cases previously performed and depending on
these data had to perform up to 20 lead-in cases23 Due to
such rigorous criteria, 116 of the 427 practicing CAS
operators were not approved for participation in the
CREST trial. In contrast, EVA-3S required much lower
prerequisites that required interventionalists perform at
least 12 CAS or five CAS if the operator had performed 35
stent procedures in the supra-aortic trunks.
In a previous report,24 the cost-effectiveness of CAS
versus CEA in patients with severe carotid stenosis was
considered to be at high surgical risk for CEA. The analysis
assumed that the rates of ipsilateral stroke, myocardial
infarction, and death were the same as those observed in the
Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial. Incre-
mental cost-effectiveness ratios (ICERs) for a 1-year post-
procedure period for CAS vs CEA treatment was $67,891
(range, -$129,372 to $379,661). Another report25 deter-
mined the cost-effectiveness of CAS with an embolic pro-
tection device versus CEA in average surgical risk patients
with moderate-to-severe carotid stenosis. The analysis as-
sumed that the rates of ipsilateral stroke, myocardial infarc-
tion, and death were the same as those observed in the
CREST trial. The estimated ICER for CAS versus CEA
treatment for a 4-year postprocedure period was $229,429.
Both analyses demonstrated an unfavorable ICER for CAS
(compared with CEA). If the rates of adverse events were
higher than those observed in clinical trials, the estimat-
ed cost per additional death ($5,000), major stroke
($26,410), minor stroke ($17,716), and myocardial infarc-
tion ($29,652) is expected to contribute negatively to the
already unfavorable ICER associated with CAS.
The next step is identification of strategies to reduce the
discrepancy between outcomes of CAS within clinical trials
and those performed outside clinical trials. One option is a
dedicated investment in outcomes research and using re-
sults to guide practices. The Report of the National Heart,
Lung, and Blood Institute (NHLBI) Working Group on
Outcomes Research26 in Cardiovascular Disease concluded
that a dedicated investment in cardiovascular outcomes
research could directly improve the care delivered in the
United States. The Karolinska Stroke Update Consensus
Statement 200427 recommended a more restrictive policy
stating that “carotid revascularization should be restricted
to centers at which the practice and complication rates are
regularly monitored by surgeons and neurologists/stroke
physicians and at which complication rates of CEA are
comparable to those found in the clinical trials demonstrat- nng efficacy. Monitoring should be prospective and inde-
endent of the surgeon involved and should be done with
onsideration of the applied indications for CEA and the
esulting case mix at each center.” Another option is to
nvolve interventionalists actively in quality improvement
nitiatives. The prospective registry, Modification of Out-
omes by Lowering Ischemic Events after Reconstruction
f Extracranial Vessels (MOLIERE)28 demonstrated that
urgeon involvement in a prospective manner is a prereq-
isite for them to evaluate, compare, and improve their
ractice. Participation in the registry ensured that indica-
ions and stroke or death rates for participating surgeons
ere ascertained and within acceptable rates.
We used the data from the NIS, which provides mini-
al details on the severity of neurological deficits, diagnos-
ic study results, and procedural details, and thereby certain
nalyses using severity or propensity adjustment could not
e performed.29,30 The NIS data also depend on the accu-
acy of diagnoses and procedures listed on discharge sum-
aries and on the data collection system. We identified
atients who participated in the IDE category B clinical
rial using a secondary diagnosis of ICD-9-CM V 70.5.
hile the accuracy of this code is not known, the code is
ssential for reimbursement from Medicare for procedures
hat are not currently reimbursed as part of routine care.
herefore, it is reasonable to assume that hospital coding
ystems would pay diligence to ensuring the accuracy of the
ode in billing claims. However, the methods of neurolog-
cal ascertainment for adverse events may be more rigorous
ith independent neurologist ascertainment in clinical tri-
ls as opposed to self-ascertainment in routine practice31
urthermore, some carotid stent trials require measure-
ent of cardiac enzymes within 24 hours, regardless of
ymptoms that may increase the detection rate of minor
yocardial ischemia32 Therefore, the rates of adverse
vents may be artificially lower in patients treated in routine
ractice due to independent surveillance and acquisition of
ests per protocol. We used primary ICD-9-CM codes for
dentifying symptomatic status, which has a true positive
ate of up to 84% in previous population-based studies.33
owever, the accuracy of codes used for identification of
arotid artery stenosis with (433.11) or without (433.10)
troke was substantially enhanced by concurrent use of
rocedures codes for CAS and CEA. Use of both primary
nd secondary diagnostic codes for identifying symptom-
tic stenosis is likely to overestimate the actual rate of
ymptomatic status, and thus certain asymptomatic patients
ere possibly classified as symptomatic in our analysis33
he discharge functional outcome cannot be measured
ith the available data, and the closest index was using the
estination of discharge as done in previous studies using
IS data.34
Our results suggest that CAS performed within clinical
rials was associated with lower rates of in-hospital mortality
nd composite endpoint of stroke, cardiac events, and
eath in the United States. These findings highlight the
eed for strategies that ensure appropriate adoption of CAS
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